Wang, X.J., Zhang, Z.Z., Wang, X.M., et al. (2024) Analysis of the Clinical Efficacy of TCM Treatment in Patients with Cerebral Infarction. Harbin Pharma, 44, 106-108.

has been cited by the following article:

• TITLE: The Study on the Effect of Huoxue Tongmai Capsules Combined with Edaravone Right Camphor on Serum Inflammatory Factors and Its Clinical Efficacy in Patients with Acute Cerebral Infarction

  AUTHORS: Yaojie Cai, Yan Chen, Yuping He

  KEYWORDS: Acute Cerebral Infarction, Huoxue Tongmai Capsule, Edaravone Right Camphor, Inflammatory Factors, Nerve Function

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.2, February 13, 2025

  ABSTRACT: Objective: To explore the therapeutic effect of Huoxue Tongmai capsule combined with edaravone right camphor on patients with acute cerebral infarction (Acute Cerebral Infarction) and the effect of combination therapy on serum inflammatory factors. Methods: In this study, 90 patients with acute cerebral infarction hospitalized in Zhuji People’s Hospital from December 2023 to December 2024 were selected and divided into two groups of 45 patients in each group. The control group used standard medical treatment, and the treatment group compared the changes of serum inflammatory factors IL-CRP, TNF-α, and Hcy with Huoxue Tongmai capsule for 7 days, 14 days and 30 days, and discussed the changes of the modified Rankin scale score (mRS) and National Institutes of Health Stroke Scale (NIHSS) score. Results: At 7 days, 14 days, and 30 days of treatment, the NIHSS score, mRS score, hs-CRP, IL-6, TNF-α, and Hcy levels were statistically significant (P α, and Hcy levels in the treatment group were significantly lower than those in the control group (P Conclusion: Patients with acute cerebral infarction received Huoxue Tongmai capsule combined with edaravone right camphor, which can reduce the inflammatory reaction, improve the nerve function and improve the prognosis.